Key result
ADIPOQ rs2241766 SNP linked to ~5-fold greater CAD risk and lower serum adiponectin.
Why the study?
Adiponectin might contribute to the development of CAD, but the association of specific ADIPOQ gene polymorphisms with CAD and adiponectin levels required investigation in a Turkish cohort.
Are ADIPOQ gene variants (rs2241766, rs1501299, rs266729) and circulating adiponectin levels associated with coronary artery disease risk in a Turkish population?
Case-Control (n=288)
No
Are ADIPOQ gene variants (rs2241766, rs1501299, rs266729) and circulating adiponectin levels associated with coronary artery disease risk in a Turkish population?
Answers are grounded in this paper and cite their sources.
The rs2241766 variant in the ADIPOQ gene is a significant genetic determinant of reduced serum adiponectin levels and increased CAD risk, suggesting its potential utility as a biomarker for risk stratification.
BACKGROUND/AIMSCoronary artery disease (CAD) is a major international health issue, closely linked with obesity and its associated metabolic complications. Adiponectin, an adipokine involved in glucose and lipid metabolism, might contribute to the development of CAD. This study investigated the association of three single nucleotide polymorphisms (SNPs) in the adiponectin gene (ADIPOQ), rs2241766, rs1501299, and rs266729, with CAD and serum adiponectin levels in a Turkish cohort. MATERIALS AND METHODS: A total of 288 participants (150 CAD patients and 138 controls) were included. Serum adiponectin levels were measured, SNP genotyping was performed, and genotype-phenotype associations were evaluated using different genetic inheritance models. We also assessed the relationships among SNPs, adiponectin levels, and CAD risk. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic value. RESULTS: Serum adiponectin was significantly lower in CAD patients. ROC analysis indicated limited diagnostic value (area under the curve=0.115, 95% confidence interval: 0.074-0.156). The rs2241766 SNP showed a significant association with CAD risk under three inheritance models. Moreover, the rs2241766 SNP was strongly associated with reduced adiponectin levels in risk allele carriers. CONCLUSION: The rs2241766 SNP in the ADIPOQ gene is significantly associated with both increased CAD risk and reduced serum adiponectin levels, suggesting its potential utility as a genetic biomarker. Additional studies are necessary to validate these findings in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Akan et al. (2026) conducted a case-control in Turkish adults with coronary artery disease defined as ≥50% stenosis in left main coronary artery or ≥70% stenosis in major epicardial coronary artery undergoing coronary artery bypass grafting, compared to age- and sex-matched controls without CAD (n=288). ADIPOQ gene genotyping (rs2241766, rs1501299, rs266729) and serum adiponectin measurement vs. Controls without CAD was evaluated on Association of ADIPOQ gene SNPs with CAD risk and serum adiponectin levels (OR=4.857 for rs2241766 TG+GG vs TT (dominant model), 95% CI 95% CI=2.948-8.001, p=<0.0001). The rs2241766 SNP of the ADIPOQ gene was associated with a 4.857-fold increased risk of CAD and lower serum adiponectin levels in Turkish adults with CAD versus controls.
Synapse has enriched 10 related papers. Consider them for comparative context: